Evidence map›Paper›PMID 24369739›Full record

ArticleJournal of the International AIDS Society2013

Antiretroviral treatment and quality of life in Africans living with HIV: 12-month follow-up in Burkina Faso.

Antoine Jaquet, Franck Garanet, Eric Balestre, Didier K Ekouevi, Jean Claude Azani, René Bognounou, Elias Dah, Jean Charlemagne Kondombo, François Dabis, Joseph Drabo

Open access · goldAbstract read
In one paragraph

Article in Journal of the International AIDS Society, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. The effect of TB treatment on health-related quality of life for people with advanced HIV.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2020
    Article
  14. Changes and determinants of health-related quality of life among people newly diagnosed with HIV in China: a 1-year follow-up study.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2019
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Bioinformatics in Africa: The Rise of Ghana?PLoS computational biology · 2015
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Antoine JaquetUniversité Bordeaux, ISPED, Centre INSERM U897 - Epidémiologie-Biostatistique, F-33000 Bordeaux, France; INSERM, ISPED, Centre INSERM U897 - Epidémiologie-Biostatistique, F-33000 Bordeaux, France; antoine.jaquet@isped.u-bordeaux2.fr.
Franck GaranetService de Médecine interne, Centre Hospitalier Universitaire Yalgado Ouedraogo (CHU-YO), Ouagadougou, Burkina Faso.
Eric BalestreUniversité Bordeaux, ISPED, Centre INSERM U897 - Epidémiologie-Biostatistique, F-33000 Bordeaux, France; INSERM, ISPED, Centre INSERM U897 - Epidémiologie-Biostatistique, F-33000 Bordeaux, France.
Didier K EkoueviUniversité Bordeaux, ISPED, Centre INSERM U897 - Epidémiologie-Biostatistique, F-33000 Bordeaux, France; INSERM, ISPED, Centre INSERM U897 - Epidémiologie-Biostatistique, F-33000 Bordeaux, France; PACCI, Centre Hospitalier Universitaire (CHU) de Treichville, Abidjan, Cote d'Ivoire.
Jean Claude AzaniPACCI, Centre Hospitalier Universitaire (CHU) de Treichville, Abidjan, Cote d'Ivoire.
René BognounouService de Médecine interne, Centre Hospitalier Universitaire Yalgado Ouedraogo (CHU-YO), Ouagadougou, Burkina Faso.
Elias DahCentre médical associatif African Association Solidarity (AAS), Ouagadougou, Burkina Faso.
Jean Charlemagne KondomboCentre médical avec antenne chirurgicale de Pisssy, Ouagadougou, Burkina Faso.
François DabisUniversité Bordeaux, ISPED, Centre INSERM U897 - Epidémiologie-Biostatistique, F-33000 Bordeaux, France; INSERM, ISPED, Centre INSERM U897 - Epidémiologie-Biostatistique, F-33000 Bordeaux, France.
Joseph DraboService de Médecine interne, Centre Hospitalier Universitaire Yalgado Ouedraogo (CHU-YO), Ouagadougou, Burkina Faso.
Bordeaux Population Health · FRCentre Hospitalier Universitaire Yalgado Ouédraogo · BFDirection Générale de la Pharmacie, du Médicament et des Laboratoires · BFInserm · FRUniversity Hospital Medical Center at Treichville · CI

Funding

WADA (West Africa Database on Antiretroviral Therapy) CollaborationU01AI069919 · NIAID · UNIVERSITY OF BORDEAUX II · PI Didier Koumavi Ekouevi, Antoine Jaquet · 2006 to 2026
$29.9M
NIAID NIH HHS 5U01AI069919NIAID NIH HHS U01 AI069919
6 · The paper itself

Abstract

introductionThe scale-up of highly active antiretroviral therapy (HAART) has led to a significant improvement in survival of the HIV-positive patient but its effects on health-related quality of life (HRQOL) are less known and context-dependent. Our aim was to assess the temporal changes and factors associated with HRQOL among HIV-positive adults initiating HAART in Burkina Faso.

methodsHIV-positive people initiating HAART were prospectively included and followed over a one-year period in three HIV clinics of Ouagadougou. HRQOL was assessed at baseline and at each follow-up visit using physical (PHS) and mental (MHS) summary scores derived from the Medical Outcome Study 36-Item short-form health survey (MOS SF-36) questionnaire. Toxicity related to HAART modification and self-reported symptoms were recorded during follow-up visits. Determinants associated with baseline and changes in both scores over a one-year period were assessed using a mixed linear model.

resultsA total of 344 patients were included. Their median age at baseline was 37 years [interquartile range (IQR) 30-44] and their median CD4 count was 181 cells/mm(3) (IQR 97-269). The mean [standard deviation (SD)] PHS score increased from 45.4 (11.1) at baseline to 60.0 (3.1) at 12 months (p <10(-4)) and the mean (SD) MHS score from 42.2 (8.7) to 43.9 (3.4) (p<10(-2)). After one year of treatment, patients that experienced on average two symptoms during follow-up presented with significantly lower PHS (63.9) and MHS (43.8) scores compared to patients that presented no symptoms with PHS and MHS of 68.2 (p<10(-4)) and 45.3 (p<10(-3)), respectively. DISCUSSION: The use of HAART was associated with a significant increase in both physical and mental aspects of the HRQOL over a 12-month period in this urban African population. Perceived symptoms experienced during follow-up visits were associated with a significant impairment in HRQOL. The appropriate and timely management of reported symptoms during the follow-up of HAART-treated patients is a key component to restore HRQOL.

Indexed as

Antiretroviral Therapy, Highly ActiveQuality of LifeAdultAnti-HIV AgentsBurkina FasoDrug-Related Side Effects and Adverse ReactionsFemaleFollow-Up StudiesHIV InfectionsHumansMaleMiddle AgedSurveys and QuestionnairesUrban PopulationAnti-HIV Agentsantiretroviral treatmentBurkina FasoHIV/AIDSquality of lifesub-Saharan Africa

Identifiers

PMID24369739
PMCPMC3871830
OpenAlexW2046090420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.